TY - JOUR T1 - Access to Biologic Therapies in Canada for Children with Juvenile Idiopathic Arthritis JF - The Journal of Rheumatology JO - J Rheumatol SP - 1875 LP - 1879 DO - 10.3899/jrheum.120089 VL - 39 IS - 9 AU - CLAIRE M.A. LEBLANC AU - BIANCA LANG AU - ALMA BENCIVENGA AU - ANNE-LAURE CHETAILLE AU - PAUL DANCEY AU - PETER DENT AU - PAIVI MIETTUNEN AU - KIEM OEN AU - ALAN ROSENBERG AU - JOHANNES ROTH AU - ROSIE SCUCCIMARRI AU - SHIRLEY M.L. TSE AU - SUSANNE BENSELER AU - DAVID A. CABRAL AU - SARAH CAMPILLO AU - GAËLLE CHÉDEVILLE AU - CIARAN M. DUFFY AU - KAREN WATANABE DUFFY AU - ELIE HADDAD AU - ADAM M. HUBER AU - RONALD LAXER AU - DEBORAH LEVY AU - NICOLE JOHNSON AU - SUZANNE RAMSEY AU - NATALIE SHIFF AU - HEINRIKE SCHMELING AU - RAYFEL SCHNEIDER AU - ELIZABETH STRINGER AU - RAE S.M. YEUNG AU - LORI B. TUCKER Y1 - 2012/09/01 UR - http://www.jrheum.org/content/39/9/1875.abstract N2 - Objective. To compare access to biologic therapies for children with juvenile idiopathic arthritis (JIA) across Canada, and to identify differences in provincial regulations and criteria for access. Methods. Between June and August 2010, we compiled the provincial guidelines for reimbursement of biologic drugs for children with JIA and conducted a multicenter Canada-wide survey of pediatric rheumatologists to determine their experience with accessing biologic therapies for their patients. Results. There were significant difficulties accessing biologic treatments other than etanercept and abatacept for children. There were large discrepancies in the access criteria and coverage of biologic agents across provinces, notably with age restrictions for younger children. Conclusion. Canadian children with JIA may not receive optimal internationally recognized “standard” care because pediatric coverage for biologic drugs through provincial formularies is limited and inconsistent across the country. There is urgent need for public policy to improve access to biologic therapies for these children to ensure optimal short-term and longterm health outcomes. ER -